Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by LB Pharmaceuticals Inc in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219607
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable and accrued expenses | 3,464 | (2,894) |
| Net cash used in operating activities | (23,290) | (8,128) |
| Investing Activities | ||
| Purchases of property and equipment | (32) | (21) |
| Proceeds from the sale of marketable securities | — | 2,501 |
| Maturities of marketable securities | — | 2,500 |
| Net cash (used in) provided by investing activities | (32) | 4,980 |
| Financing Activities |
Item 1. Financial Statements
FAQ
- What is LB Pharmaceuticals Inc's capex?
- LB Pharmaceuticals Inc (LBRX) reported capex of $32K in Q1 2026.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about LB Pharmaceuticals Inc's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude